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index, and the volume receiving 10 and 12 Gy indicating risk 
of radionecrosis. 
Results: All plans were judged clinically acceptable, but 
differences were observed in the dosimetric parameters. 
MIDCA achieved conformal plans (CI = 0.66 ± 0.07) with steep 
dose fall-off (GI = 4.47 ± 1.57), a V12 of 35.56 ± 26.41 cc and 
a V10 of 49.03 ± 38.10 cc. The VMAT plans had comparable 
conformity (0.67 ± 0.12) than MIDCA, worse GI (7.11 ± 3.12) 
and higher V10 (67.93 ± 55.93 cc) and V12 (46.34 ± 35.92 cc). 
The brain metastases software tool generated plans with 
similar CI (0.65 ± 0.08) then the two established treatment 
techniques while improving the GI (3.94 ± 1.42) and managing 
comparable V10 (48.47 ± 35.93 cc) and V12 (36.30 ± 27.09 cc) 
compared to MIDCA. 
Conclusions: Our results suggest that the automated brain 
metastases planning algorithm can achieve similar conformity 
and low dose spread compared to multi-isocenter DCA while 
increasing efficiency in both treatment planning and delivery 
due to the use of a single-isocenter approach. In terms of 
efficiency, VMAT radiosurgery was already likely to replace 
the multi-isocenter DCA technique for multiple lesions at the 
cost of increased low dose spread. Comparable efficiency was 
found with the new algorithm while improved dose gradient 
was observed suggesting that this novel software offers the 
best of both world (i.e. efficient single-isocenter DCA 
delivery). 
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Purpose/Objective: In our clinic, the treatment technique of 
choice for the majority of patients is Volumetric Arc Therapy. 
At present, paediatric medulloblastoma patients undergoing 
cranial spinal radiotherapy will be offered proton therapy 
elsewhere. Sometimes, due to bad prognoses and physical 
shape of the patient, the patient is treated locally with 
classical 3D-CRT photon fields. Overlapping posterior fields 
induces high dose maximums and the dose distribution will be 
sensitive to patient positioning. Moreover, this technique is 
prone to high heart doses and inhomogeneous target 
coverage. This study compares VMAT plans with classical 3D-
CRT plans while comparing the risk for mortality attributable 
to secondary cancer and heart toxicity using the Life Years 
Lost-principle (LYL1) as well as the risk for hematologic 
effects2. Furthermore, the VMAT plans can be optimized in a 
fashion that the dose distribution will be less sensitive to 
patient positioning and the benefit of such an approach will 
be assessed. 
Materials and Methods: Five patients were treated with the 
3D-CRT cranial spinal technique. On those patients all OAR 
were retrospectively delineated including the bone producing 
bone marrow. The VMAT plans consists of fields that are 
deliberately field overlapping, ranging from 1 to 4 cm. The 
total dose was 36 Gy in 20 fractions. The robustness of the 
dose distribution towards patient positioning errors was 
tested by moving the isocentres in the treatment plan by 5 
mm in the cranial-caudal direction. The LYL estimates were 
calculated and compared for lung and heart. The acute 
haematological toxicity was investigated by calculating the 
V3Gy of the red marrow (trombocytes) and the V2Gy 
(leukocytes), V3Gy (hæmoglobin) to the total body. 
Results: As a result, the dose max for both planning 
techniques changes according to table 1. The LYL for lungs 
increases with a factor 1.5 to 3 and the LYL for myocardial 
infarction decreases with a factor 0.5 to 1.0 when using 
VMAT. The V3Gy of the bone marrow and V3Gy, V2Gy of the body 
increases with a factor 2 when using VMAT. 
Conclusions: The VMAT technique provides a more robust 
dose distribution. The LYL principle can be used as a measure 
to compare plans and to re-optimize the dose distribution. 
The LYL estimates are intrinsically uncertain due to the 
limited knowledge of second cancer dose-response and the 
incidence profile across attained age, and the results should 
be interpreted in this context. The VMAT technique will 
induce a higher risk of acute Anaemia, leukopaenia and 
Thrombocytopaenia, but can be controlled when the patient 
is monitored daily. 
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Purpose/Objective: Varian RapidPlan™ knowledge-based 
planning software is designed to increase consistency and 
improve efficiency in treatment planning. The aim of this 
study was to compare the quality of plans produced using 
RapidPlan with those produced following local standard 
planning procedures for prostate treatments.  
Materials and Methods: A dose prediction model was trained 
using clinical treatment plans for 35 prostate patients 
previously treated with 37 fractions of 5-field IMRT. A high-
dose PTV (prostate + 0.5cm/0cm posterior margin) was 
planned to 78Gy, with additional PTVs treated to 71Gy 
(prostate + 1.0cm/0.6cm) and 60Gy (seminal vesicles + 
1.0cm) using Varian Eclipse v13.5. 10 additional patients 
previously planned using local clinical procedures were then 
replanned using the RapidPlan model to predict DVHs and 
thereby generate patient-specific initial plan optimization 
objectives. Priorities for minimum target dose objectives 
